WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 65 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in Cumulative List No. 13, 2009 (available in CD-ROM only).
Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 65 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la Liste récapitulative No. 13, 2009 (disponible sur CD-ROM seulement).
Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS: Lista 65 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en Cumulative List No. 13, 2009 (disponible sólo en CD-ROM).
49
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
Latin, English, French, Spanish: Recommended INN DCI Recommandée DCI Recomendada
Chemical name or description; Molecular formula; Graphic formula Nom chimique ou description; Formule brute; Formule développée Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
amuvatinibum amuvatinib amuvatinib amuvatinib
N-[(1,3-benzodioxol-5-yl)methyl]-4-([1]benzofuro[3,2-d]pyrimidin4-yl)piperazine-1-carbothioamide N-[(1,3-benzodioxol-5-yl)méthyl]-4-([1]benzofuro[3,2-d]pyrimidin4-yl)pipérazine-1-carbothioamide N-[(1,3-benzodioxol-5-il)metil]-4-([1]benzofuro[3,2-d]pirimidin4-il)piperazina-1-carbotioamida C23H21N5O3S N N N O N S O H N O
anagliptinum anagliptin anagliptine anagliptina
N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoéthyl}amino)2-méthylpropyl]-2-méthylpyrazolo[1,5-a]pyrimidine-6-carboxamide N-[2-({2-[(2S)-2-cianopirrolidin-1-il]-2-oxoetil}amino)-2-metilpropil]2-metilpirazolo[1,5-a]pirimidina-6-carboxamida C19H25N7O2 O N N N H 3C N H H N H3C CH3 O N H CN
50
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
atecegatranum atecegatran atécégatran atecegatrán
(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-{(2R)-2-[3-chloro5-(difluoromethoxy)phenyl]-2-hydroxyacetyl}azetidine-2-carboxamide (2S)-N-[(4-carbamimidoylphényl)méthyl]-1-{(2R)-2-[3-chloro5-(difluorométhoxy)phényl]-2-hydroxyacétyl}azétidine-2-carboxamide (2S)-N-[(4-carbamimidoilfenil)metil]-1-{(2R)-2-[3-cloro5-(difluorometoxi)fenil]-2-hidroxiacetil}azetidina-2-carboxamida C21H21ClF2N4O4 NH H2 N H N O H H OH N O O F F Cl
avibactamum avibactam avibactam avibactam
(1R,2S,5R)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane2-carboxamide (1R,2S,5R)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane2-carboxamide (1R,2S,5R)-7-oxo-6-sulfooxi-1,6-diazabiciclo[3.2.1]octano2-carboxamida C7H11N3O6S O N O O N S O HO H O NH2
H
bavisantum bavisant bavisant bavisant
(4-cyclopropylpiperazin-1-yl}){4-[(morpholin4-yl)methyl]phenyl}methanone (4-cyclopropylpipérazin-1-yl){4-[(morpholin4-yl)méthyl]phényl}méthanone (4-ciclopropilpiperazin-1-il){4-[(morfolin-4-il)metil]fenil}metanona C19H27N3O2 O O N N N
51
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
bedaquilinum bedaquiline bédaquiline bedaquilina
(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)2-(naphthalen-1-yl)-1-phenylbutan-2-ol (1R,2S)-1-(6-bromo-2-méthoxyquinoléin-3-yl)-4-(diméthylamino)2-(naphtalén-1-yl)-1-phénylbutan-2-ol (1R,2S)-1-(6-bromo-2-metoxiquinolein-3-il)-4-(dimetilamino)2-(naftalen-1-il)-1-fenilbutan-2-ol C32H31BrN2O2 N Br HO N CH3 OCH3 H
CH3
brentuximabum vedotinum # brentuximab vedotin
immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiens TNFRSF8 (tumor necrosis factor receptor superfamily member 8, KI-1, CD30)], chimeric monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-446) [Mus musculus VH (IGHV1-84*02 -(IGHD)-IGHJ3*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfide (if not conjugated) with kappa light chain (1'-218') [Mus musculus V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; (226-226'')-disulfide dimer; conjugated, on an average of 3 to 5 cysteinyl, to monomethylauristatin E (MMAE), via a maleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-valcit-PABC) linker For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"*. immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo sapiens TNFRSF8 (membre 8 de la superfamille des récepteurs du facteur de nécrose tumorale, KI-1, CD30)], anticorps monoclonal chimérique conjugué à l'auristatine E; chaîne lourde gamma1 (1-446) [Mus musculus VH (IGHV1-84*02 (IGHD)-IGHJ3*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfure (si non conjugué) avec la chaîne légère kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dimère (226-226'')-disulfure; conjugué, sur 3 à 5 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker maléimidécaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-valcit-PABC) Pour la partie védotine, veuillez vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*.
brentuximab védotine
52
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
brentuximab vedotina
inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo sapiens TNFRSF8 (miembro 8 de la superfamilia de los receptores del factor de necrosis tumoral, KI-1, CD30)], anticuerpo monoclonal quimérico conjugado con auristatina E; cadena pesada gamma1 (1-446) [Mus musculus VH (IGHV1-84*02 (IGHD)-IGHJ3*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfuro (si non está conjugado) con la cadena ligera kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dimero (226-226'')-disulfuro; conjugado, en 3 a 5 residuos cisteinil en término medio, con monometilauristatina E (MMAE), mediante un conector maleimidecaproil-valil-citrulinil-paminobenzilcarbamato (mc-val-cit-PABC) Por la parte vedotina, por favor, vaya al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*. Heavy chain / Chaîne lourde / Cadena pesada QIQLQQSGPE VVKPGASVKI SCKASGYTFT IYPGSGNTKY NEKFKGKATL TVDTSSSTAF NYWFAYWGQG TQVTVSAAST KGPSVFPLAP PEPVTVSWNS GALTSGVHTF PAVLQSSGLY NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP LMISRTPEVT CVVVDVSHED PEVKFNWYVD RVVSVLTVLH QDWLNGKEYK CKVSNKALPA LPPSRDELTK NQVSLTCLVK GFYPSDIAVE DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE Light chain / Chaîne légère / Cadena ligera DIVLTQSPAS LAVSLGQRAT ISCKASQSVD LIYAASNLES GIPARFSGSG SGTDFTLNIH TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK QWKVDNALQS GNSQESVTEQ DSKDSTYSLS THQGLSSPVT KSFNRGEC
DYYITWVKQK MQLSSLTSED SSKSTSGGTA SLSSVVTVPS APELLGGPSV GVEVHNAKTK PIEKTISKAK WESNGQPENN ALHNHYTQKS FDGDSYMNWY PVEEEDAATY SGTASVVCLL STLTLSKADY
PGQGLEWIGW TAVYFCANYG ALGCLVKDYF SSLGTQTYIC FLFPPKPKDT PREEQYNSTY GQPREPQVYT YKTTPPVLDS LSLSPG
50 100 150 200 250 300 350 400 446
QQKPGQPPKV 50 YCQQSNEDPW 100 NNFYPREAKV 150 EKHKVYACEV 200 218
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 144-200 261-321 367-425 22''-96'' 144''-200'' 261''-321'' 367''-425'' Intra-L 23'-92' 138'-198' 23'''-92''' 138'''-198''' Inter-H-L * 220-218' 220''-218''' Inter-H-H * 226-226'' 229-229'' *Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 5 drug linkers each via a thioether bond. * Deux ou trois des ponts disulfure ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 5 linker-principe actif chacun via une liaison thioéther. * Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 5 conectores de principio activo N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 297, 297''
cenicrivirocum cenicriviroc
8-{4-[2-(butoxy)ethoxy]phenyl}-1-(2-methylpropyl)-N-(4-{(S)-[(1propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenyl)-1,2,3,4-tetrahydro1-benzazocine-5-carboxamide 8-{4-[2-(butoxy)éthoxy]phényl}-1-(2-méthylpropyl)-N-(4-{(S)-[(1propyl-1H-imidazol-5-yl)méthyl]sulfinyl}phényl)-1,2,3,4-tétrahydro1-benzazocine-5-carboxamide 8-{4-[2-(butoxi)etoxi]fenil}-1-(2-metilpropil)-N-(4-{(S)-[(1-propil1H-imidazol-5-il)metil]sulfinil}fenil)-1,2,3,4-tetrahidro-1-benzazocina5-carboxamida
cénicriviroc
cenicriviroc
53
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
C41H52N4O4S H3 C CH3 H3C N H3C O S O N H
N N
O
O
cobicistatum cobicistat
(1,3-thiazol-5-yl)methyl (5S,8R,11R)-8,11-dibenzyl-2-methyl5-[2-(morpholin-4-yl)ethyl]-1-[2-(propan-2-yl)-1,3-thiazol-4-yl]3,6-dioxo-2,4,7,12-tetraazatridecan-13-oate (5S,8R,11R)-8,11-dibenzyl-2-méthyl-5-[2-(morpholin-4-yl)éthyl]1-[2-(propan-2-yl)-1,3-thiazol-4-yl]-3,6-dioxo-2,4,7,12tétraazatridécan-13-oate de (1,3-thiazol-5-yl)méthyle (5S,8R,11R)-8,11-dibencil-2-metil-5-[2-(morfolin-4-il)etil]1-[2-(propan-2-il)-1,3-tiazol-4-il]-3,6-dioxo-2,4,7,12-tetraazatridecan13-oato de (1,3-tiazol-5-il)metilo C40H53N7O5S2 O N O H3C H3C N S N CH3 N H H H N H O O S N
cobicistat
cobicistat
H N H
O
crizotinibum crizotinib crizotinib crizotinib
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)1H-pyrazol-4-yl]pyridin-2-amine 3-[(1R)-1-(2,6-dichloro-3-fluorophényl)éthoxy]-5-[1-(pipéridin-4-yl)1H-pyrazol-4-yl]pyridin-2-amine 3-[(1R)-1-(2,6-dicloro-3-fluorofenil)etoxi]-5-[1-(piperidin-4-il)1H-pirazol-4-il]piridin-2-amina C21H22Cl2FN5O N NH2 H CH3 Cl O N Cl F
N
HN
54
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
dacomitinibum dacomitinib dacomitinib dacomitinib
(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin6-yl}-4-(piperidin-1-yl)but-2-enamide (2E)-N-{4-[(3-chloro-4-fluorophényl)amino]-7-méthoxyquinazolin -6-yl}-4-(pipéridin-1-yl)but-2-énamide (2E)-N-{4-[(3-cloro-4-fluorofenil)amino]-7-metoxiquinazolin-6-il}4-(piperidin-1-il)but-2-enamida C24H25ClFN5O2 H3CO HN N O HN N N Cl F
dexpramipexolum dexpramipexole dexpramipexole dexpramipexol
(6R)-N -propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine (6R)-N -propyl-4,5,6,7-tétrahydro-1,3-benzothiazole-2,6-diamine (6R)-N -propil-4,5,6,7-tetrahidro-1,3-benzotiazol-2,6-diamina C10H17N3S H HN H3C S NH2 N 6 6
6
drozitumabum # drozitumab
immunoglobulin G1-lambda, anti-[Homo sapiens TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, DR5, death receptor 5, TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2, TR-2, CD262)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfide with lambda light chain (1'-213') [Homo sapiens V-LAMBDA (IGLV3-19*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; (230230'':233-233'')-bisdisulfide dimer immunoglobuline G1-lambda, anti-[Homo sapiens TNFRSF10B (membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale, DR5, death receptor 5, TRAIL-R2, récepteur 2 du ligand inducteur d'une apoptose liée au TNF, TR-2, CD262)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-451) [Homo sapiens VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfure avec la chaîne légère lambda (1'-213') [Homo sapiens V-LAMBDA (IGLV319*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; dimère (230-230'':233-233'')-bisdisulfure
drozitumab
55
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
drozitumab
inmunoglobulina G1-lambda, anti-[Homo sapiens TNFRSF10B (miembro 10B de la superfamilia de receptores del factor de necrosis tumoral, DR5, receptor de muerte 5, TRAIL-R2, receptor 2 del ligando inductor de la apoptosis de la familiaTNF, TR-2, CD262)], anticuerpo monoclonal de Homo sapiens ; cadena pesada gamma1 (1-451) [Homo sapiens VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfuro con la cadena ligera lambda (1'-213') [Homo sapiens V-LAMBDA (IGLV319*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; dímero (230-230'':233-233'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLVQSGGG VERPGGSLRL SCAASGFTFD INWQGGSTGY ADSVKGRVTI SRDNAKNSLY GAGRGWYFDY WGKGTTVTVS SASTKGPSVF KDYFPEPVTV SWNSGALTSG VHTFPAVLQS TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PKDTLMISRT PEVTCVVVDV SHEDPEVKFN NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS K Light chain / Chaîne légère / Cadena ligera SELTQDPAVS VALGQTVRIT CSGDSLRSYY NRPSGIPDRF SGSSSGNTAS LTITGAQAED GTKLTVLGQP KAAPSVTLFP PSSEELQANK ADSSPVKAGV ETTTPSKQSN NKYAASSYLS STVEKTVAPT ECS
DYAMSWVRQA LQMNSLRAED PLAPSSKSTS SGLYSLSSVV PPCPAPELLG WYVDGVEVHN ALPAPIEKTI IAVEWESNGQ VMHEALHNHY
PGKGLEWVSG TAVYYCAKIL GGTAALGCLV TVPSSSLGTQ GPSVFLFPPK AKTKPREEQY SKAKGQPREP PENNYKTTPP TQKSLSLSPG
50 100 150 200 250 300 350 400 450 451
ASWYQQKPGQ EADYYCNSAD ATLVCLISDF LTPEQWKSHK
APVLVIYGAN 50 SSGNHVVFGG 100 YPGAVTVAWK 150 SYSCQVTHEG 200 213
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 148-204 265-325 371-429 22''-96'' 148''-204'' 265''-325'' 371''-429'' Intra-L 21'-86' 135'-194' 21'''-86''' 135'''-194''' Inter-H-L 224-212' 224''-212''' Inter-H-H 230-230'' 233-233'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 301, 301''
dulaglutidum # dulaglutide
glucagon-like peptide-1-immunoglobulin G4 fusion protein, [2-glycyl,16-L-glutamyl,30-glycyl][human glucagon-like peptide 1-(737)-peptide] {(8-A>G,22-G>E,36-R>G)-GLP-1(7-37)} fusion protein with tris(tetraglycyl-L-seryl)-L-alanine (linker) fusion protein with des276-lysine-[57-L-proline,63-L-alanine,64-L-alanine]human immunoglobulin G4 Fc region {(10-S>P)-H-(4-F>A,5-L>A)-CH2-(107K>-)-CH3 of IGHG4*01}, dimer (55-55':58-58')-bisdisulfide protéine de fusion entre le peptide 1 semblable au glucagon et l'immunoglobuline G4, [2-glycyl,16-L-glutamyl,30-glycyl][peptide 1 semblable au glucagon humain-(7-37)-peptide] {(8-A>G,22-G>E,36-R>G)GLP-1(7-37)} protéine de fusion avec le tris(tétraglycyl-L-séryl)-L-alanine (lien) protéine de fusion avec la dès-276-lysine-[57-L-proline,63-Lalanine,64-L-alanine]région Fc de l'immunoglobuline G4 humaine {(10-S>P)H-(4-F>A,5-L>A)CH2-(107-K>-)CH3 du IGHG4*01}, (5555':58-58')-bisdisulfure du dimère
dulaglutide
56
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
dulaglutida
proteína de fusión entre el péptido similar al glucagón 1 y la inmunoglobulina G4, [2-glicil,16-L-glutamil,30-glicil][péptido similar al glucagón humano 1(7-37)-péptido] {(8-A>G,22-G>E,36-R>G)GLP-1(7-37)} proteína de fusión con el tris(tetraglicil-L-seril)-L-alanina (vínculo) proteína de fusión con la des-276-lisina-[57-L-prolina, 63-L-alanina,64-Lalanina]región Fc de la inmunoglobulina G4 humana {(10-S>P)H-(4F>A,5-L>A)CH2-(107-K>-)CH3 del IGHG4*01}, (55-55':58-58')bisdisulfuro del dímero C2646H4044N704O836S18 Monomer / Monomère / Monomero HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL EVQFNWYVDG VEVHNAKTKP REEQFNSTYR KVSNKGLPSS IEKTISKAKG QPREPQVYTL FYPSDIAVEW ESNGQPENNY KTTPPVLDSD VFSCSVMHEA LHNHYTQKSL SLSLG GGGGGSGGGG MISRTPEVTC VVSVLTVLHQ PPSQEEMTKN GSFFLYSRLT SGGGGSAESK VVVDVSQEDP DWLNGKEYKC QVSLTCLVKG VDKSRWQEGN 50 100 150 200 250 275
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 55-55' 58-58' 90-150 90'-150' 196-254 196'-254'
eliglustatum eliglustat éliglustat eliglustat
N-{(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy3-(pyrrolidin-1-yl)propan-2-yl}octanamide N-{(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy3-(pyrrolidin-1-yl)propan-2-yl}octanamide N-{(1R,2R)-1-(2,3-dihidro-1,4-benzodioxin-6-il)-1-hidroxi-3-(pirrolidin1-il)propan-2-il}octanamida C23H36N2O4
N O H3C N H H
O O
H OH
elpamotidum elpamotide
L-arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-α-aspartylglycylL-asparaginyl-L-arginyl-L-isoleucine
human soluble (Vascular Endothelial Growth Factor Receptor) VEGFR2-(169-177)-peptide elpamotide L-arginyl-L-phénylalanyl-L-valyl-L-prolyl-L-α-aspartylglycylL-asparaginyl-L-arginyl-L-isoleucine
(Récepteur du Facteur de Croissance de l'Endothélium Vasculaire) RFCEV2 soluble humain-(169-177)-peptide elpamotida L-arginil-L-fenilalanil-L-valil-L-prolil-L-α-aspartilglicil-L-asparaginilL-arginil-L-isoleucina
(receptor del factor de crecimiento endotelial vascular) RFCEV2 soluble humano-(169-177)-péptido C47H76N16O13 H Arg Phe Val Pro Asp Gly Asn Arg Ile OH 9
57
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
ensituximabum # ensituximab
immunoglobulin G1-kappa, anti-[Homo sapiens MUC5AC (mucin 5AC, mucin 5 subtypes A and C tracheobronchial/gastric)], chimeric monoclonal antibody; gamma1 heavy chain (1-443) [Mus musculus VH (IGHV2-3*01 (IGHD)-IGHJ4*01) [8.7.7] (1-113) -Homo sapiens IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfide with kappa light chain (1'-213') [Mus musculus V-KAPPA (IGKV4-70*01 IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; (222-222'':225-225'')-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens MUC5AC (mucine 5AC, mucine 5 de sous-types A et C trachéo-bronchique/gastrique)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-443) [Mus musculus VH (IGHV2-3*01 (IGHD)-IGHJ4*01) [8.7.7] (1-113) -Homo sapiens IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfure avec la chaîne légère kappa (1'-213') [Mus musculus V-KAPPA (IGKV470*01 -IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'213')]; dimère (222-222'':225-225'')-bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens MUC5AC (mucina 5AC, mucina 5 de subtipos A y C traqueo-bronquial/gástrico], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-443) [Mus musculus VH (IGHV2-3*01 (IGHD)-IGHJ4*01) [8.7.7] (1-113) -Homo sapiens IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfuro con la cadena ligera kappa (1'-213') [Mus musculus V-KAPPA (IGKV4-70*01 IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dímero (222-222'':225-225'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLKESGPD LVAPSQSLSI TCTVSGFSLS IWGDGSTSYN SGLISRLSIS KENSKSQVFL DYWGHGTSVT VSSASTKGPS VFPLAPSSKS TVSWNSGALT SGVHTFPAVL QSSGPYSLSS KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV VLTVLHQDWL NGKEYKCKVS NKALPAPIEK RDELTKNQVS LTCLVKGFYP SDIAVEWESN FLYSKLTVDK SRWQQGNVFS CSVMHEALHN Light chain / Chaîne légère / Cadena ligera QVVLTQSPVI MSASPGEKVT MTCSASSSIS SKLASGVPAR FSGSGSGTSY SLTISNMEAG TNLEIKRTVA APSVFIFPPS DEQLKSGTAS NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SSPVTKSFNR GEC
ensituximab
ensituximab
KFGVNWVRQP KLNSLQADDT TSGGTAALGC VVTVPSSSLG LGGPSVFLFP HNAKTKPREE TISKAKGQPR GQPENNYKTM HYTQKSLSLS YMYWYQQKPG DAATYYCHQR VVCLLNNFYP SKADYEKHKV
PGKGLEWLGV ATYYCVKPGG LVKDYFPEPV TQTYICNVNH PKPKDTLMIS QYNSTYRVVS EPQVYTLPPS PPVLDSDGSF PGK
50 100 150 200 250 300 350 400 443
TSPKRWIYDT 50 DSYPWTFGGG 100 REAKVQWKVD 150 YACEVTHQGL 200 213
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-95 140-196 257-317 363-421 22''-95'' 140''-196'' 257''-317'' 363''-421'' Intra-L 23'-87' 133'-193' 23'''-87''' 133'''-193''' Inter-H-L 216-213' 216''-213''' Inter-H-H 222-222'' 225-225'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 293, 293''
58
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
eteplirsenum eteplirsen
all-P-ambo-5'-{P-[4-({2-[2-(2hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-N,Ndimethylphosphonamidate}-P,2',3'-trideoxy-P-dimethylamino-2',3'imino-2',3'-secocytidylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino-2',3'imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-trideoxy-Pdimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'secocytidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino2',3'-secoadenylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino-2',3'imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-trideoxy-Pdimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'secoguanylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino2',3'-secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino2',3'-imino-2',3'-secoguanylyl-(2'a→5')-P,2',3'-trideoxy-Pdimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-P,3'-dideoxyP-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a→5')P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'-secoguanylyl(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'secocytidylyl-(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino2',3'-secoadenylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino-2',3'imino-2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-dimethylamino2',3'-imino-2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-Pdimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'trideoxy-P-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')P,3'-dideoxy-P-dimethylamino-2',3'-imino-2',3'-secothymidylyl(2'a→5')-P,2',3'-trideoxy-P-dimethylamino-2',3'-imino-2',3'secoadenylyl-(2'a→5')-2',3'-dideoxy-2',3'-imino-2',3'-secoguanosine
59
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
étéplirsen
tout-P-ambo-5'-{P-[4-({2-[2-(2hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-N,Ndiméthylphosphonamidate}-P,2',3'-tridésoxy-P-diméthylamino-2',3'imino-2',3'-sécocytidylyl-(2'a→5')-P,3'-didésoxy-P-diméthylamino2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridésoxy-Pdiméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-P,2',3'tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'sécoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino2',3'-sécocytidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'imino-2',3'-sécoadénylyl-(2'a→5')-P,3'-didésoxy-P-diméthylamino2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridésoxy-Pdiméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-P,2',3'tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'sécoguanylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino2',3'-sécoguanylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridésoxy-Pdiméthylamino-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-P,2',3'tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')P,3'-didésoxy-P-diméthylamino-2',3'-imino-2',3'-sécothymidylyl(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'sécoguanylyl-(2'a→5')-P,2',3'-tridéoxy-P-diméthylamino-2',3'-imino2',3'-sécoguanylyl-(2'a→5')-P,2',3'-tridéoxy-P-diméthylamino-2',3'imino-2',3'-sécocytidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,3'-didésoxy-Pdiméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,3'didésoxy-P-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')P,3'-didésoxy-P-diméthylamino-2',3'-imino-2',3'-sécothymidylyl(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'sécocytidylyl-(2'a→5')-P,3'-didésoxy-P-diméthylamino-2',3'-imino2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'imino-2',3'-sécoadenylyl-(2'a→5')-2',3'-didésoxy-2',3'-imino-2',3'sécoguanosine
60
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
eteplirsén
todo-P-ambo-5'-{P-[4-({2-[2-(2hidroxietoxi)etoxi]etoxi}carbonl)piperazin-1-il]-N,Ndimetilfosfonamidato}-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino2',3'-secocitidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-2',3'-imino2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-Pdimetilamino-2',3'-imino-2',3'-secoadenil-(2'a→5')-P,2',3'-tridesoxi-Pdimetilamino-2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxiP-dimetilamino-2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,2',3'tridesoxi-P-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-2',3'-secoadenilil(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino-2',3'secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino2',3'-secoadenilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino-2',3'-imino2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'-imino2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino-2',3'imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secoadenill-(2'a→5')-P,3'-didesoxi-P-dimetilamino2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'-didesoxi-P-dimetilamino2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-dimetilamino2',3'-imino-2',3'-secoadenilil-(2'a→5')-2',3'-didesoxi-2',3'-imino-2',3'secoguanosina C364H569N177O122P30 O O HO 3
B(n) N N P O 5'
B(30) O
O 1' 2'a
N
P
O
NH
n = 1 - 29
H3 C N O CH3
H3 C N O CH3
29
B(1-30): C-T-C-C-A-A-C-A-T-C-A-A-G-G-A-A-G-A-T-G-G-C-A-T-T-T-C-T-A-G
61
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
fasitibanti chloridum fasitibant chloride
(4S)-4-amino-5-{4-[4-(2,4-dichloro-3-{[(2,4-dimethylquinolin8-yl)oxy]methyl}benzenesulfonamido)oxane-4-carbonyl]piperazin1-yl}-N,N,N-trimethyl-5-oxopentan-1-aminium chloride chlorure de (4S)-4-amino-5-{4-[4-(2,4-dichloro-3-{[(2,4diméthylquinoléin-8-yl)oxy]méthyl}benzènesulfonamido)oxane4-carbonyl]pipérazin-1-yl}-N,N,N-triméthyl-5-oxopentan-1-aminium cloruro de (4S)-4-amino-5-{4-[4-(2,4-dicloro-3-{[(2,4-dimetilquinolein8-il)oxi]metil}bencenosulfonamido)oxano-4-carbonil]piperazin-1-il}N,N,N-trimetil-5-oxopentan-1-aminio C36H49Cl3N6O6S Cl O N H3 C CH3 Cl S H N O N N O O H NH2
chlorure de fasitibant
cloruro de fasitibant
Cl CH3 N CH3 CH3
O O
fedovapagonum fedovapagon
(2S)-N ,N -dimethyl-N -{[2-methyl-4-(2,3,4,5-tetrahydro1H-1-benzazepine-1-carbonyl)phenyl]methyl}pyrrolidine1,2-dicarboxamide (2S)-N ,N -diméthyl-N -{[2-méthyl-4-(2,3,4,5-tétrahydro1H-1-benzazépine-1-carbonyl)phényl]méthyl}pyrrolidine1,2-dicarboxamide (2S)-N ,N -dimetil-N -{[2-metil-4-(2,3,4,5-tetrahidro1H-1-benzazepina-1-carbonil)fenil]metil}pirrolidina1,2-dicarboxamida C27H34N4O3 O N H CH3 O N O H N CH3 2 2 1 2 2 1
2
2
1
fédovapagon
fedovapagón
CH3
N
florbetapirum ( F) 18 florbetapir ( F) florbétapir ( F) florbetapir ( F) 18 18
18
4-[(1E)-2-(6-{2-[2-(2-[ F]fluoroethoxy)ethoxy]ethoxy}pyridine3-yl)ethen-1-yl]-N-methylaniline 4-[(1E)-2-(6-{2-[2-(2-[ F]fluoroéthoxy)éthoxy]éthoxy}pyridin3-yl)éthén-1-yl]-N-méthylaniline 4-[(1E)-2-(6-{2-[2-(2-[ F]fluoroetoxi)etoxi]etoxi}piridin-3-il)eten-1-il]N-metilanilina 18 18
18
62
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C20H25 FN2O3 H N
18
H3 C
N
O
O
O
[18F]
fluciclatidum ( F) 18 fluciclatide ( F)
18
N -[(28E)-29-(4-[ F]fluorophenyl)-5,25-dioxo-3,9,12,15,18,21,272 heptaoxa-6,24,28-triazanonacos-28-enoyl]-N -(sulfanylacetyl)L-lysyl-L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-cysteinylL-phenylalanyl-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa12-azaheptadecyl)-L-cysteinamide cyclic (2→6)-disulfide cyclic (1→8)-thioether (2→6)-disulfure cyclique et (1→8)-thioéther cyclique du N -[(28E)18 29-(4-[ F]fluorophényl)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa2 6,24,28-triazanonacos-28-énoyl]-N -(2-sulfanylacétyl)-L-lysylL-cystéinyl-L-arginylglycyl-L-α-aspartyl-L-cystéinyl-L-phénylalanyl1-N-(17-amino-13,17-dioxo-3,6,9,15-tétraoxa-12-azaheptadécyl)L-cystéinamide (2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del N -[(28E)-29-(418 [ F]fluorofenil)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-6,24,282 triazanonacos-28-enoil]-N -(2-sulfanilacetil)-L-lisil-L-cisteinilL-arginilglicil-L-α-aspartil-L-cisteinil-L-fenilalanil-1-N-(17-amino13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecil)-L-cisteinamida C75H115 FN18O27S3 O H2N O O N H S Lys O N6 18 6 6
6
18
fluciclatide ( F)
18
fluciclatida ( F)
18
O
O H O N H
Cys O
Arg O
Gly
Asp O O
Cys
Phe
N H O O
O
O
N H O
O
N [ F] 18
N H
O
fluciclovinum ( F) 18 fluciclovine ( F) fluciclovine ( F) fluciclovina ( F) 18 18
18
(1r,3r)-1-amino-3[ F]fluorocyclobutane-1-carboxylic acid acide trans-1-amino-3-[ F]fluorocyclobutane-1-carboxylique ácido (1r,3r)-1-amino-3-[ F]fluorociclobutano-1-carboxílico C5H8 FNO2 H [18F] NH2 CO2H 18 18 18
18
63
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
flurpiridazum ( F) 18 flurpiridaz ( F) flurpiridaz ( F) flurpiridaz ( F) 18 18
18
2-tert-butyl-4-chloro-5-({4-[(218 [ F]fluoroethoxy)methyl]phenyl}methoxy)pyridazin-3(2H)-one 2-tert-butyl-4-chloro-5-({4-[(218 [ F]fluoroéthoxy)méthyl]phényl}méthoxy)pyridazin-3(2H)-one 2-terc-butil-4-cloro-5-({4-[(218 [ F]fluoroetoxi)metil]fenil}metoxi)piridazin-3(2H)-ona C18H22Cl FN2O3 H3 C H3C CH3 O N N Cl O O [18F] 18
foralumabum # foralumab
immunoglobulin G1-kappa, anti-[Homo sapiens CD3E (CD3 epsilon)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (227227'':230-230'')-bisdisulfide dimer immunoglobuline G1 -kappa, anti-[Homo sapiens CD3E (CD3 epsilon)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-448) [Homo sapiens (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo sapiens V-KAPPA (IGKV311*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (227-227'':230-230'')-bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens CD3E (CD3 epsilon)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-448) [Homo sapiens (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA (IGKV311*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (227-227'':230-230'')-bisdisulfuro
foralumab
foralumab
64
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGRSLRL SCAASGFKFS IWYDGSKKYY VDSVKGRFTI SRDNSKNTLY GYWHFDLWGR GTLVTVSSAS TKGPSVFPLA FPEPVTVSWN SGALTSGVHT FPAVLQSSGL CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC TLMISRTPEV TCVVVDVSHE DPEVKFNWYV YRVVSVLTVL HQDWLNGKEY KCKVSNKALP TLPPSREEMT KNQVSLTCLV KGFYPSDIAV SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCRASQSVS ASNRATGIPA RFSGSGSGTD FTLTISSLEP GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT VDNALQSGNS QESVTEQDSK DSTYSLSSTL GLSSPVTKSF NRGEC
GYGMHWVRQA LQMNSLRAED PSSKSTSGGT YSLSSVVTVP PAPEAEGGPS DGVEVHNAKT APIEKTISKA EWESNGQPEN EALHNHYTQK SYLAWYQQKP EDFAVYYCQQ ASVVCLLNNF TLSKADYEKH
PGKGLEWVAV TAVYYCARQM AALGCLVKDY SSSLGTQTYI VFLFPPKPKD KPREEQYNST KGQPREPQVY NYKTTPPVLD SLSLSPGK
50 100 150 200 250 300 350 400 448
GQAPRLLIYD 50 RSNWPPLTFG 100 YPREAKVQWK 150 KVYACEVTHQ 200 215
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 145-201 262-322 368-426 22''-96'' 145''-201'' 262''-322'' 368''-426'' Intra-L 23'-88' 135'-195' 23'''-88''' 135'''-195''' Inter-H-L 221-215' 221''-215''' Inter-H-H 227-227'' 230-230'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 298, 298''
fosdevirinum fosdevirine fosdévirine fosdevirina
methyl (R)-(2-carbamoyl-5-chloro-1H-indol-3-yl){3-[(1E)-2cyanoethen-1-yl]-5-methylphenyl}phosphinate (R)-(2-carbamoyl-5-chloro-1H-indol-3-yl){3-[(1E)-2-cyanoéthén-1-yl]5-méthylphényl}phosphinate de méthyle (R)-(2-carbamoil-5-cloro-1H-indol-3-il){3-[(1E)-2-cianoeten-1-il]5-metilfenil}fosfinato de metilo C20H17ClN3O3P O NH2 O O CH3 P
CN
HN
CH3 Cl
ganitumabum # ganitumab
immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120449)], (222-219')-disulfide with kappa light chain (1'-219') [Homo sapiens V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'112') -IGKC*01 (113'-219')]; (228-228'':231-231'')-bisdisulfide dimer
65
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
ganitumab
immunoglobuline G1-kappa, anti-[Homo sapiens IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline, IGF1-R, IGF-1R, CD221)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimère (228-228'':231-231'')bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens IGF1R (receptor del factor de crecimiento 1 análogo a la insulina, IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dímero (228-228'':231-231'')bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLQESGPG LVKPSGTLSL TCAVSGGSIS EIYHSGSTNY NPSLKSRVTI SVDKSKNQFS GRTDAFDIWG QGTMVTVSSA STKGPSVFPL YFPEPVTVSW NSGALTSGVH TFPAVLQSSG ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP DTLMISRTPE VTCVVVDVSH EDPEVKFNWY TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM Light chain / Chaîne légère / Cadena ligera DVVMTQSPLS LPVTPGEPAS ISCRSSQSLL LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL VQWKVDNALQ SGNSQESVTE QDSKDSTYSL VTHQGLSSPV TKSFNRGEC SSNWWSWVRQ LKLSSVTAAD APSSKSTSGG LYSLSSVVTV CPAPELLGGP VDGVEVHNAK PAPIEKTISK VEWESNGQPE HEALHNHYTQ HSNGYNYLDW SRVEAEDVGV KSGTASVVCL SSTLTLSKAD PPGKGLEWIG TAVYYCARWT TAALGCLVKD PSSSLGTQTY SVFLFPPKPK TKPREEQYNS AKGQPREPQV NNYKTTPPVL KSLSLSPGK 50 100 150 200 250 300 350 400 449
ganitumab
YLQKPGQSPQ 50 YYCMQGTHWP 100 LNNFYPREAK 150 YEKHKVYACE 200 219
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 146-202 263-323 369-427 22''-96'' 146''-202'' 263''-323'' 369''-427'' Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L 222-219' 222''-219''' Inter-H-H 228-228'' 231-231'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 299, 299''
gataparsenum gataparsen
all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thioucytidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-O-(2methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-Pthioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine
66
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
gataparsen
tout-P-ambo-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-O-(2méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-Pthioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyluridine todo-P-ambo-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-Ptiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-Ptiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-Ptioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5metiluridina C204H278N59O111P17S17 (3'→5')d(P-thio)(rU-rG-rU-rG-C-T-A-T-T-C-T-G-T-G-rA-rA-rU-rU) Modified nucleosides / Nucléosides modifiés / Nucleosidos modificados: N H2 N A G N OH O N N OCH3 HO O HO O CH3 OCH3 HO O HO OH OH O N N NH2 CH3 OH O N N OCH3 H N N NH2 N NH O
gataparsén
U OH O
O
C O O
gemigliptinum gemigliptin gémigliptine gemigliptina
1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one 1-{(2S)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropipéridin-2-one 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona
67
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
C18H19F8N5O2 CF3 N F3C N N O H NH2 F F N O
iniparibum iniparib iniparib iniparib
4-iodo-3-nitrobenzamide 4-iodo-3-nitrobenzamide 4-iodo-3-nitrobenzamida C7H5IN2O3 I O2N O NH2
insulinum tregopilum insulin tregopil insuline trégopil insulina tregopilo
N N N
6,29B
-(4,7,10,13-tetraoxatetradecanoyl)human insulin -(4,7,10,13-tétraoxatétradécanoyl)insuline humaine -(4,7,10,13-tetraoxatetradecanoil)insulina humana
6,29B
6,29B
C267H401N65O82S6 H Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu 10
Glu Asn Tyr Cys Asn OH 20
H Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr 10
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr OH 30 20 N6 O O H3C O O O
ioflubenzamidum ( I) 131 ioflubenzamide ( I) ioflubenzamide ( ioflubenzamida ( 131
131
N-[2-(diethylamino)ethyl]-4-(4-fluorobenzamido)-5-[ 2-methoxybenzamide N-[2-(diéthylamino)éthyl]-4-(4-fluorobenzamido)-5-[ 2-méthoxybenzamide N-[2-(dietilamino)etil]-4-(4-fluorobenzamido)-5-[ 2-metoxibenzamida 131
131
I]iodoI]iodo-
I) I)
131
131
I]iodo-
68
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C21H25F
131
IN3O3 O [ O 131
CH3 N H N CH3
I]
N H F
OCH3
ioforminolum ioforminol
all-ambo-5,5'-[2-hydroxypropane1,3-diylbis(formylazanediyl)]bis[N,N'-bis(2,3-dihydroxypropyl)2,4,6-triiodobenzene-1,3-dicarboxamide] tout-ambo-5,5'-[2-hydroxypropane1,3-diylbis(formylazanediyl)]bis[N,N'-bis(2,3-dihydroxypropyl)2,4,6-triiodobenzène-1,3-dicarboxamide] todo-ambo-5,5'-[2-hidroxipropano-1,3-diilbis(formilazanodiil)]bis[N,N'bis(2,3-dihidroxipropil)-2,4,6-triiodobenceno-1,3-dicarboxamida] C33H40I6N6O15 OH HO OH HO I H N O I O H N H N I H N O I O OH OH OH OH
ioforminol
ioforminol
O I N OH I N
O
ipragliflozinum ipragliflozin ipragliflozine ipragliflozina
(1S)-1,5-anhydro-1-C-{3-[(1-benzothiophen-2-yl)methyl]4-fluorophenyl}-D-glucitol (1S)-1,5-anhydro-1-C-{3-[(1-benzothiophén-2-yl)méthyl]4-fluorophényl}-D-glucitol (1S)-1,5-anhidro-1-C-{3-[(1-benzotiofen-2-il)metil]-4-fluorofenil}D-glucitol C21H21FO5S
S
F
HO O OH HO OH
69
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
itarnafloxinum itarnafloxin
5-fluoro-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-3-oxo-6-[(3RS)-3(pyrazin-2-yl)pyrrolidin-1-yl]-3H-benzo[b]pyrido[3,2,1-kl]phenoxazine2-carboxamide 5-fluoro-N-{2-[(2S)-1-méthylpyrrolidin-2-yl]éthyl}]-3-oxo-6-[3-(pyrazin2-yl)pyrrolidin-1-yl]-3H-benzo[b]pyrido[3,2,1-kl]phénoxazine2-carboxamide 5-fluoro-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-3-oxo-6-[(3RS)-3(pirazin-2-il)pirrolidin-1-il]-3H-benzo[b]pirido[3,2,1-kl]fenoxazina2-carboxamida C35H33FN6O3
itarnafloxine
itarnafloxina
N N
H *
O N F O O N
and epimer at C* et l'épimère en C* y el epímero al C*
H N H N CH3
itolizumabum # itolizumab
immunoglobulin G1-kappa, anti-[Homo sapiens CD6 (Tp120, T12)], humanized monoclonal antibody; gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens CD6 (Tp120, T12)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV117*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (228-228":231-231")bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens CD6 (Tp120, T12)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-449) [VH humanizado (Homo sapiens IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV117*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (228-228":231-231")bisdisulfuro
itolizumab
itolizumab
70
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVKPGGSLKL SCAASGFKFS ISSGGSYIYY PDSVKGRFTI SRDNVKNTLY YDLDYFDSWG QGTLVTVSSA STKGPSVFPL YFPEPVTVSW NSGALTSGVH TFPAVLQSSG ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP DTLMISRTPE VTCVVVDVSH EDPEVKFNWY TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCKASRDIR ATSLADGVPS RFSGSGSGQD YSLTISSLES GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC
RYAMSWVRQA LQMSSLRSED APSSKSTSGG LYSLSSVVTV CPAPELLGGP VDGVEVHNAK PAPIEKTISK VEWESNGQPE HEALHNHYTQ SYLTWYQQKP DDTATYYCLQ SVVCLLNNFY LSKADYEKHK
PGKRLEWVAT TAMYYCARRD TAALGCLVKD PSSSLGTQTY SVFLFPPKPK TKPREEQYNS AKGQPREPQV NNYKTTPPVL KSLSLSPGK
50 100 150 200 250 300 350 400 449
GKAPKTLIYY 50 HGESPFTLGS 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 146-202 263-323 369-427 22''-96'' 146''-202'' 263''-323'' 369''-427'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 222-214' 222''-214''' Inter-H-H 228-228'' 231-231'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 299, 299''
lorvotuzumabum mertansinum # lorvotuzumab mertansine
immunoglobulin G1-kappa, anti-[Homo sapiens NCAM1 (neural cell adhesion molecule 1, CD56, NCAM-1)], humanized monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-448) [humanized VH (Homo sapiens IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01 (119-448)], (221-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (227-227":230-230")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a thiopentanoate linker For the mertansine part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"* immunoglobuline G1-kappa, anti-[Homo sapiens NCAM1 (molécule d'adhésion 1 de cellule neurale, CD56, NCAM-1)], anticorps monoclonal humanisé conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01 (119-448)], (221-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (227-227":230-230")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker thiopentanoate Pour la partie mertansine, veuillez vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*.
lorvotuzumab mertansine
71
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
lorvotuzumab mertansina
inmunoglobulina G1-kappa, anti-[Homo sapiens NCAM1 (molécula de adhesión 1 de celula neural, CD56, NCAM-1)], anticuerpo monoclonal humanizado conjugado con maitansinoide DM1; cadena pesada gamma1 (1-448) [VH humanizado (Homo sapiens IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01 (119-448)], (221-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV230*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimero (227-227":230-230")-bisdisulfuro; conjugado, en 3 a 4 residuos lisil por término medio, con maitansinoide DM1 con un conector tiopentanoato Por la parte mertansina, por favor, vaya al documento "INN for pharmaceutical substances: Names for radicals, groups & others"*. Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGRSLRL SCAASGFTFS ISSGSFTIYY ADSVKGRFTI SRDNSKNTLY KGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA FPEPVTVSWN SGALTSGVHT FPAVLQSSGL CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC TLMISRTPEV TCVVVDVSHE DPEVKFNWYV YRVVSVLTVL HQDWLNGKEY KCKVSNKALP TLPPSRDELT KNQVSLTCLV KGFYPSDIAV SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH Light chain / Chaîne légère / Cadena ligera DVVMTQSPLS LPVTLGQPAS ISCRSSQIII RLIYKVSNRF SGVPDRFSGS GSGTDFTLKI HTFGQGTKVE IKRTVAAPSV FIFPPSDEQL VQWKVDNALQ SGNSQESVTE QDSKDSTYSL VTHQGLSSPV TKSFNRGEC
SFGMHWVRQA LQMNSLRAED PSSKSTSGGT YSLSSVVTVP PAPELLGGPS DGVEVHNAKT APIEKTISKA EWESNGQPEN EALHNHYTQK HSDGNTYLEW SRVEAEDVGV KSGTASVVCL SSTLTLSKAD
PGKGLEWVAY TAVYYCARMR AALGCLVKDY SSSLGTQTYI VFLFPPKPKD KPREEQYNST KGQPREPQVY NYKTTPPVLD SLSLSPGK
50 100 150 200 250 300 350 400 448
FQQRPGQSPR 50 YYCFQGSHVP 100 LNNFYPREAK 150 YEKHKVYACE 200 219
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 145-201 262-322 368-426 22''-96'' 145''-201'' 262''-322'' 368''-426'' Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L 221-219' 221''-219''' Inter-H-H 227-227'' 230-230'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 298, 298''
maraciclatidum maraciclatide
N -(5-{[5-{[3-(hydroxyimino)-2-methylbutan-2-yl]amino}-3-(2-{[3(hydroxyimino)-2-methylbutan-2-yl]amino}ethyl)pentyl]amino}2 5-oxopentanoyl)-N -(2-sulfanylacetyl)-L-lysyl-L-cysteinylL-arginylglycyl-L-α-aspartyl-L-cysteinyl-L-phenylalanyl-N-(17-amino13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecyl)-L-cysteinamide cyclic (2→6)-disulfide cyclic (1→8)-thioether (2→6)-disulfure cyclique et (1→8)-thioéther cyclique du N -(5-{[5-{[3(hydroxyimino)-2-méthylbutan-2-yl]amino}-3-(2-{[3-(hydroxyimino)2-méthylbutan-2-yl]amino}éthyl)pentyl]amino}-5-oxopentanoyl)2 N -(2-sulfanylacétyl)-L-lysyl-L-cystéinyl-L-arginylglycyl-L-α-aspartylL-cystéinyl-L-phénylalanyl-1-N-(17-amino-13,17-dioxo-3,6,9,15tétraoxa-12-azaheptadécyl)-L-cystéinamide (2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del N -(5-{[5-{[3(hidroxiimino)-2-metilbutan-2-il]amino}-3-(2-{[2-(hidroxiimino)2-metilbutan-2-il]amino}etil)pentil]amino}-5-oxopentanoil)2 N -(2-sulfanilacetil)-L-lisil-L-cisteinil-L-ar3inilglicil-L-α-aspartilL-cisteinil-L-fenilalanil-1-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa12-azaheptadecil)-L-cisteinamida 6 6
6
maraciclatide
maraciclatida
72
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C72H120N20O21S3 O H2N O O N H S Lys O N6
O
O H O N H
Cys
Arg O
Gly
Asp
Cys
Phe
N H
O
O HO H3C CH3 N CH3 N H
NH H3C CH3 N H N CH3 OH
metformini glycinas metformin glycinate glycinate de metformine glicinato de metformina
N,N-dimethyl-1,2,3-triimidodicarbonic diamide glycinate (1:1) glycinate du diamide N,N-diméthyl-1,2,3-triimidodicarbonique (1:1) glicinato de la diamida N,N-dimetil-1,2,3-triimidodicarbóníco (1:1) C4H11N5 . C2H5NO2 NH H2N N H NH N CH3
.
H2N
CO2H
CH3
mibampatorum mibampator mibampator mibampator
N-[(2R)-2-{4'-[2-(methanesulfonamido)ethyl][1,1'-biphenyl]4-yl}propyl]propane-2-sulfonamide N-[(2R)-2-{4'-[2-(méthanesulfonamido)éthyl][1,1'-biphényl]4-yl}propyl]propane-2-sulfonamide N-[(2R)-2-{4'-[2-(metanosulfonamido)etil][1,1'-bifenil]4-il}propil]propano-2-sulfonamida C21H30N2O4S2 H N S CH3
O O O O H3C S N H CH3
H
CH3
73
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
navitoclaxum navitoclax
4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en1-yl]methyl}piperazin-1-yl)-N-(4-{[(2R)-4-(morpholin-4-yl)1-(phenylsulfanyl)butan-2-yl]amino}3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en1-yl]methyl}piperazin-1-yl)-N-(4-{[(2R)-4-(morpholin-4-yl)1-(phenylsulfanyl)butan-2-yl]amino}3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide 4-(4-{[2-(4- clorofenil)-5,5- dimetilciclohex -1-en-1-il]metil}piperazin1-il)-N-(4-{[(2R)-1-(fenilsulfanil)-4-(morfolin-4-il)-butan-2-il]amino}3-(trifluorometanosulfonil)bencenosulfonil]benzamida C47H55ClF3N5O6S3 O H3 C CH3 N N S N O Cl H O O N H S O O S NH CF3
navitoclax
navitoclax
nonacogum beta pegolum # nonacog beta pegol
pegylated human blood coagulation factor IX; human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), en average of one sialyl unit of the N-linked carbohydrates are 5-N-[N-({2,3-bis[ωmethoxypoly(oxyethane-1,2-diyl)]propoxy}carbonyl)glycyl]5-N-deacetyl facteur IX humain de coagulation sanguine, pégylé; facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophile B) dont quelques unités sialyl, en moyenne une par molécule d'enzyme, de la partie N-glycosyl sont 5-N-[N({2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}carbonyl)glycyl]5-N-désacétyl factor IX humano de coagulación sanguínea, pegilado; factor IX humano de coagulación (EC 3.4.21.22, factor Christmas, factor antihemofilico B) algunas de cuyas unidades sialil, una por molécula de enzima, por término medio, de la fracción N-glicosil son 5-N-[N-({2,3-bis[ω-metoxipoli(oxietilen)]propoxi}carbonil)glicil]5-N-desacetil
nonacog bêta pégol
nonacog beta pegol
74
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
YNSGKLEEFV CESNPCLNGG NSADNKVVCS PDVDYVNSTE KVDAFCGGSI IRIIPHHNYN KFGSGYVSGW AGFHEGGRDS VSRYVNWIKE
QGNLERECME SCKDDINSYE CTEGYRLAEN AETILDNITQ VNEKWIVTAA AAINKYNHDI GRVFHKGRSA CQGDSGGPHV KTKLT
EKCSFEEARE CWCPFGFEGK QKSCEPAVPF STQSFNDFTR HCVETGVKIT ALLELDEPLV LVLQYLRVPL TEVEGTSFLT
VFENTERTTE NCELDVTCNI PCGRVSVSQT VVGGEDAKPG VVAGEHNIEE LNSYVTPICI VDRATCLRST GIISWGEECA
FWKQYVDGDQ KNGRCEQFCK SKLTRAEAVF QFPWQVVLNG TEHTEQKRNV ADKEYTNIFL KFTIYNNMFC MKGKYGIYTK
50 100 150 200 250 300 350 400 415
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 18-23 51-62 56-71 73-82 88-99 95-109 111-124 132-289 206-222 336-350 361-389 Modified residues / Résidus modifiés / Residuos modifícados E 7-8-15-17-20-21-26-27-30-33-36-40 4-carboxyGlu
HO2C HO 2C
H
NH2 CO 2H
Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-167 Asn-157 R→3-β-Gal→3-β-Gl-N→2-α-Man→6R'→3-β-Gal→3-β-Gl-N→2-α-Man→3-
β-Man→4-β-Gl-N→4-β-Gl-N→N
R = α-Sia, R' = α-Sia or PEG-α-Sia or R' = α-Sia, R = α-Sia or PEG-α-Sia Gal = D-galactopyranosyl Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl Man = D-mannopyranosyl PEG- = O-[α-methylpoly(oxyethylene) hydrogen phosphate] Sia = 5-N-acetyl-α-neuramin-2-yl Other positions of post-translational modifications: partial-hydroxylation of Asp64; O-linked glycosylation on positions Ser53 and Ser61, partially O-linked glycosylation on positions Thr159 and Thr169 Autres positions de modifications post-traductionelles: hydroxylation partielle de Asp64; glycosylation O-liée sur les positions Sér53 et Sér61, glycosylation partielle O-liée sur les positions Thr159 et Thr169 Otras posiciones de modificaciones post-traducción hidroxilación parcial de Asp64; glicosilación O-ligada en las posiciones Ser53 y Ser61, glicosilación parcial O-ligada en las posiciones Thr159 y Thr169
obinutuzumabum # obinutuzumab
immunoglobulin G1, anti-[Homo sapiens CD20 (membrane-spanning 4-domains subfamily A member 1, MS4A1, B lymphocyte surface antigen B1, Leu-16, Bp35)], humanized monoclonal antibody, GA101; gamma1 heavy chain (1-448) [humanized VH (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (228-228'':231-231'')-bisdisulfide dimer immunomodulator immunoglobuline G1, anti-[Homo sapiens CD20 (membre 1 de la sous-famille A à 4 domaines transmembranaires, MS4A1, antigène de surface B1 des lymphocytes B, Leu-16, Bp35)], anticorps monoclonal humanisé, GA101; chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') Homo sapiens IGKC*01 (113'-219')]; dimère (228-228'':231-231'')bisdisulfure immunomodulateur 75
obinutuzumab
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
obinutuzumab
inmunoglobulina G1, anti-[Homo sapiens CD20 (miembro 1 de la sub-familia A de 4 dominios transmembranarios, MS4A1, antígeno de superficie B1 de los linfocitos B, Leu-16, Bp35)], anticuerpo monoclonal humanizado, GA101; cadena pesada gamma1 (1-448) [VH humanizada (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) Homo sapiens IGHG1*01 (120-448)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') Homo sapiens IGKC*01 (113'-219')]; dímero (228-228'':231-231'')bisdisulfuro inmunomodulador Heavy chain / Chaîne lourde / Cadena pesada
QVQLVQSGAE IFPGDGDTDY FDGYWLVYWG YFPEPVTVSW ICNVNHKPSN DTLMISRTPE TYRVVSVLTV YTLPPSRDEL DSDGSFFLYS DIVMTQTPLS LLIYQMSNLV YTFGGGTKVE VQWKVDNALQ VTHQGLSSPV
VKKPGSSVKV NGKFKGRVTI QGTLVTVSSA NSGALTSGVH TKVDKKVEPK VTCVVVDVSH LHQDWLNGKE TKNQVSLTCL KLTVDKSRWQ LPVTPGEPAS SGVPDRFSGS IKRTVAAPSV SGNSQESVTE TKSFNRGEC
SCKASGYAFS TADKSTSTAY STKGPSVFPL TFPAVLQSSG SCDKTHTCPP EDPEVKFNWY YKCKVSNKAL VKGFYPSDIA QGNVFSCSVM ISCRSSKSLL GSGTDFTLKI FIFPPSDEQL QDSKDSTYSL
YSWINWVRQA MELSSLRSED APSSKSTSGG LYSLSSVVTV CPAPELLGGP VDGVEVHNAK PAPIEKTISK VEWESNGQPE HEALHNHYTQ HSNGITYLYW SRVEAEDVGV KSGTASVVCL SSTLTLSKAD
PGQGLEWMGR TAVYYCARNV TAALGCLVKD PSSSLGTQTY SVFLFPPKPK TKPREEQYNS AKGQPREPQV NNYKTTPPVL KSLSLSPGK YLQKPGQSPQ YYCAQNLELP LNNFYPREAK YEKHKVYACE
50 100 150 200 250 300 350 400 449
Light chain / Chaîne légère / Cadena ligera 50' 100' 150' 200' 219'
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-96 22''-96'' 23'-93' 23'''-93''' 139'-199' 139'''-199''' 146-202 146''-202'' 219'-222 219'''-222'' 228-228'' 231-231'' 263-323 263''-323'' 369-427 369''-427'' Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Ser-53 Ser-61 Asn-157 Thr-159 Asn-167 Thr-169
olaratumabum # olaratumab
immunoglobulin G1-kappa, anti-[Homo sapiens PDGFRA (plateletderived growth factor receptor alpha subunit, CD140a, PDGFR2)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-457) [Homo sapiens VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (236-236'':239-239'')bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens PDGFRA (sousunité alpha du récepteur du facteur de croissance dérivé des plaquettes, CD140a, PDGFR2)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-457) [Homo sapiens VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (236-236'':239-239'')bisdisulfure
olaratumab
76
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
olaratumab
inmunoglobulina G1-kappa, anti-[Homo sapiens PDGFRA (subunidad alfa del receptor del factor de crecimiento derivado de las plaquetas, CD140a, PDGFR2)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-457) [Homo sapiens VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimero (236-236'':239-239'')bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QLQLQESGPG LVKPSETLSL TCTVSGGSIN GSFFYTGSTY YNPSLRSRLT ISVDTSKNQF STYYYGSGNY YGWFDRWDQG TLVTVSSAST ALGCLVKDYF PEPVTVSWNS GALTSGVHTF SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC FLFPPKPKDT LMISRTPEVT CVVVDVSHED PREEQYNSTY RVVSVLTVLH QDWLNGKEYK GQPREPQVYT LPPSREEMTK NQVSLTCLVK YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG LSLSPGK Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCRASQSVS ASNRATGIPA RFSGSGSGTD FTLTISSLEP GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC SSSYYWGWLR SLMLSSVTAA KGPSVFPLAP PAVLQSSGLY DKTHTCPPCP PEVKFNWYVD CKVSNKALPA GFYPSDIAVE NVFSCSVMHE QSPGKGLEWI DTAVYYCARQ SSKSTSGGTA SLSSVVTVPS APELLGGPSV GVEVHNAKTK PIEKTISKAK WESNGQPENN ALHNHYTQKS 50 100 150 200 250 300 350 400 450 457
SYLAWYQQKP EDFAVYYCQQ SVVCLLNNFY LSKADYEKHK
GQAPRLLIYD 50 RSNWPPAFGQ 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-97 154-210 271-331 377-435 22''-97'' 154''-210'' 271''-331'' 377''-435'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 230-214' 230''-214''' Inter-H-H 236-236'' 239-239'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 30, 30'', 307, 307''
olokizumabum # olokizumab
immunoglobulin G4-kappa, anti-[Homo sapiens IL6 (interleukin 6; IL6)], humanized monoclonal antibody; gamma4 heavy chain (1-447) [humanized VH (Homo sapiens IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo sapiens IGHG4*01 hinge S10(228)>P (121-447)], (134-214')disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; (226-226":229-229")bisdisulfide dimer immunoglobuline G4-kappa, anti-[Homo sapiens Homo sapiens IL6 (interleukine 6; IL-6)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-447) [VH humanisé (Homo sapiens IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo sapiens IGHG4*01 charnière S10(228)>P (121-447)], (134-214')disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; dimère (226-226":229-229")bisdisulfure
olokizumab
77
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
olokizumab
inmunoglobulina G4-kappa, anti-[Homo sapiens Homo sapiens IL6 (interleukina 6; IL-6)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-447) [VH humanizado (Homo sapiens IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -Homo sapiens IGHG4*01 bisagra S10(228)>P (121-447)], (134-214')disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; dímero (226-226":229-229")bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVQPGGSLRL SCAASGFNFN MRNKNYQYGT YYAESLEGRF TISRDDSKNS ESYYGFTSYW GQGTLVTVSS ASTKGPSVFP DYFPEPVTVS WNSGALTSGV HTFPAVLQSS YTCNVDHKPS NTKVDKRVES KYGPPCPPCP LMISRTPEVT CVVVDVSQED PEVQFNWYVD RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCQASQDIG ANNLADGVPS RFSGSGSGTD FTLTISSLQP GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC DYFMNWVRQA LYLQMNSLKT LAPCSRSTSE GLYSLSSVVT APEFLGGPSV GVEVHNAKTK SIEKTISKAK WESNGQPENN ALHNHYTQKS ISLSWYQQKP EDFATYYCLQ SVVCLLNNFY LSKADYEKHK PGKGLEWVAQ EDTAVYYCAR STAALGCLVK VPSSSLGTKT FLFPPKPKDT PREEQFNSTY GQPREPQVYT YKTTPPVLDS LSLSLGK 50 100 150 200 250 300 350 400 447
GKAPKLLIYN 50 HNSAPYTFGQ 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-98 147-203 261-321 367-425 22''-98'' 147''-203'' 261''-321'' 367''-425'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 134-214' 134''-214''' Inter-H-H 226-226'' 229-229'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 297, 297''
opicaponum opicapone opicapone opicapona
2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl]4,6-dimethylpyridine N-oxide N-oxyde de 2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophényl)1,2,4-oxadiazol-3-yl]-4,6-diméthylpyridine N-óxido de 2,5-dicloro-3-[5-(3,4-dihidroxi-5-nitrofenil)1,2,4-oxadiazol-3-il]-4,6-dimetilpiridina C15H10Cl2N4O6 H3C O O2 N HO OH N CH3 N Cl N O Cl
orantinibum orantinib orantinib orantinib
3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1,2-dihydro-3H-indol3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid acide 3-(2,4-diméthyl-5-{[(3Z)-2-oxo-1,2-dihydro-3H-indol3-ylidène]méhyl}-1H-pyrrol-3-yl)propanoïque ácido 3-(2,4-dimetil-5-{[(3Z)-2-oxo-1,2-dihidro-3H-indol3-ilideno]metil}-1H-pirrol-3-il)propanoico
78
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C18H18N2O3 H N O H N CH3 CO2H H3C
oxelumabum # oxelumab
immunoglobulin G1-kappa, anti-[Homo sapiens TNFSF4 (Tumor necrosis factor ligand superfamily member 4, OX40 ligand, OX-40L, TAX transcriptionally-activated glycoprotein 1, TXGP1, gp34, CD252], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfide with kappa light chain (1'214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (100.00%) IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (229-229'':232232'')-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens TNFSF4 (membre 4 de la superfamille des ligands du facteur de nécrose tumorale, ligand de OX40, OX40L, glycoprotéine 1 activée transcriptionellement par TAX, TXGP1, CD252], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (229229'':232-232'')-bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens TNFSF4 (miembro 4 de la superfamilia de ligandos del factor de necrosis tumoral, ligando de OX40, OX40L, glicoproteína 1 activada por transcripción por TAX, TXGP1, CD252 ], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimero (229229'':232-232'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLLESGGG LVQPGGSLRL SCAASGFTFN ISGSGGFTYY ADSVKGRFTI SRDNSRTTLY LVAPGTFDYW GQGALVTVSS ASTKGPSVFP DYFPEPVTVS WNSGALTSGV HTFPAVLQSS YICNVNHKPS NTKVDKKVEP KSCDKTHTCP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW STYRVVSVLT VLHQDWLNGK EYKCKVSNKA VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCRASQGIS ASSLQSGVPS RFSGSGSGTD FTLTISSLQP GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC SYAMSWVRQA LQMNSLRAED LAPSSKSTSG GLYSLSSVVT PCPAPELLGG YVDGVEVHNA LPAPIEKTIS AVEWESNGQP MHEALHNHYT SWLAWYQQKP EDFATYYCQQ SVVCLLNNFY LSKADYEKHK PGKGLEWVSI TAVYYCAKDR GTAALGCLVK VPSSSLGTQT PSVFLFPPKP KTKPREEQYN KAKGQPREPQ ENNYKTTPPV QKSLSLSPG 50 100 150 200 250 300 350 400 449
oxélumab
oxelumab
EKAPKSLIYA 50 YNSYPYTFGQ 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 147-203 264-324 370-428 22''-96'' 147''-203'' 264''-324'' 370''-428'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 223-214' 223''-214''' Inter-H-H 229-229'' 232-232'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 300, 300''
79
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
pegdinetanibum # pegdinetanib
94 residues protein derived from human fibronectin 10 type III domain, pegylated: glycyl[1438-L-arginine(D>R),1439-L-histidine(A>H),1441-Lhistidine(A>H),1442-L-phenylalanine(V>F),1443-Lproline(T>P),1444-L-threonine(V>T),1467-L-leucine(G>L),1468-Lglutamine(S>Q),1469-L-proline(K>P),1470-L-proline(S>P),1492-Laspartic acid(G>D),1493-glycine(R>G),1494-L-arginine(G>R),1495L-asparagine(D>N),1496-glycine(S>G),1497-L-arginine(P>R),1498-Lleucine(A>L),1499-L-leucine(S>L),1501-L-isoleucine(K>I),1515-S[(3RS)-1-(1-{[α-methylpoly(oxyethylene)]carbamoyl}-3-[({[αmethylpoly(oxyethylene)]carbamoyl}oxy)methyl]-8,13-dioxo1,4-dioxa-9,12-diazapentadecan-15-yl)-2,5-dioxopyrrolidin-3-yl]L-cysteine(S>C)]human fibronectin-(1424-1516)-peptide domaine de type III de la protéine de 94 résidus derivée du 10 fibronectine humaine pégylée : glycyl[1438-L-arginine(D>R),1439-L-histidine(A>H),1441-Lhistidine(A>H),1442-L-phénylalanine(V>F),1443-Lproline(T>P),1444-L-thréonine(V>T),1467-L-leucine(G>L),1468-Lglutamine(S>Q),1469-L-proline(K>P),1470-L-proline(S>P),1492acide L-aspartique(G>D),1493-glycine(R>G),1494-Larginine(G>R),1495-L-asparagine(D>N),1496-glycine(S>G),1497-Larginine(P>R),1498-L-leucine(A>L),1499-L-leucine(S>L),1501-Lisoleucine(K>I),1515-S-[(3RS)-1-(1-{[αméthylpoly(oxyéthylène)]carbamoyl}-3-[({[αméthylpoly(oxyéthylène)]carbamoyl}oxy)méthyl]-8,13-dioxo1,4-dioxa-9,12-diazapentadécan-15-yl)-2,5-dioxopyrrolidin-3-yl]L-cystéine(S>C)]fibronectine humaine-(1424-1516)-peptide proteína de 94 residuos derivada del décimo dominio de tipo III de la fibronectina humana pegilada : glicil[1438-L-arginina(D>R),1439-L-histidina(A>H),1441-Lhistidina(A>H),1442-L-fenilalanina(V>F),1443-L-prolina(T>P),1444-Ltreonina(V>T),1467-L-leucina(G>L),1468-L-glutamina(S>Q),1469-Lprolina(K>P),1470-L-prolina(S>P),1492-ácido Laspártico(G>D),1493-glicina(R>G),1494-L-arginina(G>R),1495-Lasparagina(D>N),1496-glicina(S>G),1497-L-arginina(P>R),1498-Lleucina(A>L),1499-L-leucina(S>L),1501-L-isoleucina(K>I),1515-S[(3RS)-1-(1-{[α-metilpoli(oxietileno)]carbamoil}-3-[({[αmetilpoli(oxietileno)]carbamoil}oxi)metil]-8,13-dioxo-1,4-dioxa9,12-diazapentadecan-15-il)-2,5-dioxopirrolidin-3-il]L-cisteína(S>C)]fibronectina humana-(1424-1516)-péptido GEVVAATP TSLLISWRHP HFPTRYYRIT 1450 YGETGGNSPV QEFTVPLQPP TATISGLKPG VDYTITVYAV TDGRNGRLLS 1500 IPISINYRTE IDKPCQ 1516 Modified residue / Résidu modifié / Residuo modificado C 1515 pegylated cystein cystéine pégylée cisteína pegilada ème
th
pegdinétanib
pegdinetanib
O H3C O H N n
H N NH O O O N
O O
O H S H N H
H3C
O
H N n
O O
n # 450
O
80
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
peginesatidum # peginesatide
pegylated erythropoietin receptor agonist, 6.21 6.21' 2 6 N ,N -{[(N ,N -bis{[ω-methoxypoly(oxyethylene)]carbonyl}L-lysyl-β-alanyl)imino]bis(methylenecarbonyl)}bis[Nacetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidylL-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(naphthalen-1-yl)L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginylN-methylglycyl-L-lysinamide] (6→15:6'→15')-bisdisulfure cyclic agoniste du récepteur de l'érythropoïétine, pégylé 6.21 6.21' 2 6 (6→15:6'→15')-bisdisulfure cyclique du N ,N -{[(N ,N -bis{[ωméthoxypoly(oxyéthylène)]carbonyl}-L-lysylβ-alanyl)imino]bis(méthylènecarbonyl)}bis[acétylglycylglycyl-L-leucylL-tyrosyl-L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolylL-isoleucyl-L-thréonyl-3-(naphtalén-1-yl)-L-alanyl-L-valyl-L-cystéinylL-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-méthylglycyl-L-lysinamide] agonista del receptor de la eritropoyetina, pegilado 6.21 6.21' 2 6 (6→15:6'→15')-bisdisulfuro cíclico del N ,N -{[(N ,N -bis{[ωmetoxipoli(oxietileno)]carbonil}-L-lisil6 15 β-alanil)imino]bis(metilenocarbonil)}bis{S ,S -ciclo[N-acetilglicilglicilL-leucil-L-tirosil-L-alanil-L-cisteinil-L-histidil-L-metionilglicil-L-prolilL-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-L-valil-L-cisteinilL-glutaminil-L-prolil-L-leucil-L-arginil-N-metilglicil-L-lisinamida] C231H350N62O58S6[C2H4O]n O Gly Gly Leu Tyr Ala Cys His Met Gly H3C Pro Ile Thr Nal Val Cys Gln Pro Leu Arg Sar Lys NH2 10
péginésatide
peginesatida
O H3C O O a
20
N6
N H O H N H O NH O
O N O
n = a + b # 900
H3C O
O
O
b
Gly Gly Leu Tyr Ala Cys His Met Gly H3C N6 Pro Ile Thr Nal Val Cys Gln Pro Leu Arg Sar Lys NH2 10' 20'
3-(naphthalen-1yl)-L-alanyl
Sar H
=
N CH3 O
Nal
=
N-methylglycyl
N H
O
81
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
ponesimodum ponesimod
(2Z,5Z)-5-{3-chloro-4-[(2R)-2,3dihydroxypropoxy]phenylmethylidene}-3-(2-methylphenyl)2-(propylimino)-1,3-thiazolidin-4-one (2Z,5Z)-5-{3-chloro-4-[(2R)-2,3dihydroxypropoxy]phénylméthylidène}-3-(2-méthylphényl)2-(propylimino)-1,3-thiazolidin-4-one (2Z,5Z)-5-{3-cloro-4-[(2R)-2,3-dihidroxipropoxi]fenilmetilideno}3-(2-metilfenil)-2-(propilimino)-1,3-tiazolidin-4-ona C23H25CIN2O4S O N CH3 N CH3 S Cl O H OH OH
ponésimod
ponesimod
rezatomidinum rezatomidine rézatomidine rezatomidina
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydro-2H-imidazol2-thione 4-[(1S)-1-(2,3-diméthylphényl)éthyl]-1,3-dihydro-2H-imidazole2-thione 4-[(1S)-1-(2,3-dimetilfenil)etil]-1,3-dihidro-2H-imidazol-2-tiona C13H16N2S H N S H3C CH3 H CH3 N H
roledumabum # roledumab
immunoglobulin G1-kappa, anti-[Homo sapiens RHD (Rhesus blood group D antigen, RhD, CD240D)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-456) [Homo sapiens VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfide with kappa light chain (1'-214') [Homo sapiens VKAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (235-235'':238-238'')-bisdisulfide dimer
82
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
rolédumab
immunoglobuline G1-kappa, anti-[Homo sapiens RHD (antigène groupe sanguin Rhésus D, RhD, CD240D)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-456) [Homo sapiens VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (235235'':238-238'')-bisdisulfure inmunoglobulina G1-kappa, anti-[Homo sapiens RHD (antígeno sanguíneo D Rhesus, RhD, CD240D)], anticuerpo monoclonal de Homo sapiens ; cadena pesada gamma1 (1-456) [Homo sapiens VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (235235'':238-238'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGRSLRL SCTASGFTFK ISYDGRNIQY ADSVKGRFTF SRDNSQDTLY RSRWLQLGLE DAFHIWGQGT MVTVSSASTK LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP SLGTQTYICN VNHKPSNTKV DKKVEPKSCD LFPPKPKDTL MISRTPEVTC VVVDVSHEDP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC QPREPQVYTL PPSRDELTKN QVSLTCLVKG KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN SLSPGK Light chain / Chaîne légère / Cadena ligera AIRMTQSPSS FSASTGDRVT ITCRASQDIR ASTLQSGVPS RFSGSGSGTD FTLTINSLQS GTRVEITRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC NYAMHWVRQA LQLNSLRPED GPSVFPLAPS AVLQSSGLYS KTHTCPPCPA EVKFNWYVDG KVSNKALPAP FYPSDIAVEW VFSCSVMHEA PAKGLEWVAT TAVYYCARPV SKSTSGGTAA LSSVVTVPSS PELLGGPSVF VEVHNAKTKP IEKTISKAKG ESNGQPENNY LHNHYTQKSL 50 100 150 200 250 300 350 400 450 456
roledumab
NYVAWYQQKS EDFATYYCQQ SVVCLLNNFY LSKADYEKHK
GKAPKFLIYA 50 YYNSPPTFGQ 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 153-209 270-330 376-434 22''-96'' 153''-209'' 270''-330'' 376''-434'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 229-214' 229''-214''' Inter-H-H 235-235'' 238-238'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 306, 306''
ruxolitinibum ruxolitinib ruxolitinib ruxolitinib
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol1-yl]propanenitrile (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol1-yl]propanenitrile (3R)-3-ciclopentil-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol1-il]propanonitrilo
83
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
C17H18N6 H N N HN N N CN
samalizumabum # samalizumab
immunoglobulin G2-kappa, anti-[Homo sapiens CD200 (OX-2)], humanized monoclonal antibody; gamma2 heavy chain (1-442) [humanized VH (Homo sapiens IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -Homo sapiens IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (219-219":220220":223-223":226-226")-tetrakisdisulfide dimer immunoglobuline G2-kappa, anti-[Homo sapiens CD200 (OX-2)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-442) [VH humanisé (Homo sapiens IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -Homo sapiens IGHG2*01 CH1-charnière-CH2 1.6-1.1 (118232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (219-219":220-220":223-223":226-226")-tétrakisdisulfure inmunoglobulina G2-kappa, anti-[Homo sapiens CD200 (OX-2)], anticuerpo monoclonal humanizado; cadena pesado gamma2 (1442) [humanizado VH (Homo sapiens IGHV1-69*01 (73.50%) (IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -Homo sapiens IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1125, CH3 1-129 K130>del (233-442)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada(Homo sapiens IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (219-219":220-220":223223":226-226")-tetrakisdisulfuro
samalizumab
samalizumab
84
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
Heavy chain / Chaîne lourde / Cadena pesada QVQLQQSGSE LKKPGASVKI SCKASGYSFT IDPYYGSSNY NLKFKGRVTI TADQSTTTAY RDYFDYWGQG TTLTVSSAST KGPSVFPLAP PEPVTVSWNS GALTSGVHTF PAVLQSSGLY NVDHKPSNTK VDKTVERKCC VECPPCPAPP RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK QEEMTKNQVS LTCLVKGFYP SDIAVEWESN FLYSRLTVDK SRWQEGNVFS CSVMHEALHN Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASIGDRVT ITCKASQDIN ANRLVDGVPS RFSGSGSGTD YTLTISSLQP GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC
DYIILWVRQN MELSSLRSED CSRSTSESTA SLSSVVTVPS VAGPSVFLFP HNAKTKPREE TISKAKGQPR GQPENNYKTT HYTQKSLSLS SYLSWFQQKP EDFAVYYCLQ SVVCLLNNFY LSKADYEKHK
PGKGLEWIGH TAVYYCGRSK ALGCLVKDYF SNFGTQTYTC PKPKDTLMIS QFNSTYRVVS EPQVYTLPPS PPVLDSDGSF LG
50 100 150 200 250 300 350 400 442
GKAPKLLIYR 50 YDEFPYTFGG 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 144-200 257-317 363-421 22''-96'' 144''-200'' 257''-317'' 363''-421'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 131-214' 131''-214''' Inter-H-H 219-219'' 220-220'' 223-223'' 226-226'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 293, 293''
simenepagum simenepag siménépag simenepag
5-({[(2R)-1-{4-[(1S)-1-hydroxyhexyl]phenyl}-5-oxopyrrolidin2-yl]methoxy}methyl)thiophene-2-carboxylic acid acide 5-({[(2R)-1-{4-[(1S)-1-hydroxyhexyl]phényl}-5-oxopyrrolidin2-yl]méthoxy}méthyl)thiophène-2-carboxylique ácido 5-({[(2R)-1-{4-[(1S)-1-hidroxihexil]fenil}-5-oxopirrolidin2-il]metoxi}metil)tiofeno-2- carboxílico C23H29NO5S H O N O H OH CH3 S CO2H
somatropinum pegolum # somatropin pegol
-[(2E)-({2-[({2,3-bis[ω-methoxypoly(oxyethylene)]propoxy}= N carbonyl)amino]ethoxy}imino)ethyl]human somatotropin (growth hormone) -[(2E)-({2-[({2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}= N carbonyl)amino]éthoxy}imino)éthyl]somatotropine humaine (hormone de croissance) -[(2E)-({2-[({2,3-bis[ω-metoxipoli(oxietileno)]propoxi}carbonil)= N amino]etoxi}imino)etil]somatotropina humana (hormona de crecimiento) 5.141 5.141
5.141
somatropine pégol
somatropina pegol
85
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
FPTIPLSRLF SLCFSESIPT LVYGASDSNV HNDDALLKNY
DNAMLRAHRL PSNREETQQK YDLLKDLEEG GLLYCFRKDM
HQLAFDTYQE SNLELLRISL IQTLMGRLED DKVETFLRIV
FEEAYIPKEQ LLIQSWLEPV GSPRTGQIFK QCRSVEGSCG
KYSFLQNPQT 50 QFLRSVFANS 100 QTYSKFDTNS 150 F 191
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 53-165 182-189 Modified residue / Résidu modifié / Residuo modificado H3 C Q Gln(141) H3 C O O O n
O O
H N
O
N
NH O H
n
O
n # 480
N H
O
taprenepagum taprenepag taprénépag taprenepag
2-{3-[(N-{[4-(1H-pyrazol-1-yl)phenyl]methyl}pyridine3-sulfonamido)methyl]phenoxy}acetic acid acide 2-{3-[(N-{[4-(1H-pyrazol-1-yl)phényl]méthyl}pyridine3-sulfonamido)méthyl]phénoxy}acétique ácido 2-{3-[(N-{[4-(1H-pirazol-1-il)fenil]metil}piridina3-sulfonamido)metil]fenoxi}acético C24H22N4O5S O CO2H
N N S O O N N
tedalinabum tedalinab tédalinab tedalinab
(4S,7R)-N-tert-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro1H-4,7-methanoindazole-3-carboxamide (4S,7R)-N-tert-butyl-1-(2,4-difluorophényl)-4,5,6,7-tétrahydro1H-4,7-méthanoindazole-3-carboxamide (4S,7R)-N-terc-butil-1-(2,4-difluorofenil)-4,5,6,7-tetrahidro1H-4,7-metanoindazol-3-carboxamida C19H21F2N3O F N F H H N O H3C N H CH3 CH3
86
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
tegobuvirum tegobuvir tégobuvir tegobuvir
5-({6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine 5-({6-[2,4-bis(trifluorométhyl)phényl]pyridazin-3-yl}méthyl)2-(2-fluorophényl)-5H-imidazo[4,5-c]pyridine 5-({6-[2,4-bis(trifluorometil)fenil]piridazin-3-il}metil)-2-(2-fluorofenil)5H-imidazo[4,5-c]piridina C25H14F7N5 F3C F N CF3 N N N N
telapristonum telapristone télapristone telapristona
11β-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy19-norpregna-4,9-diene-3,20-dione 11β-[4-(diméthylamino)phényl]-17-hydroxy-21-méthoxy19-norprégna-4,9-diène-3,20-dione 11β-[4-(dimetilamino)fenil]-17-hidroxi-21-metoxi-19-norpregna4,9-dieno-3,20-diona C29H37NO4 CH3 H3C N H H H O O CH3 O CH3
OH
temanogrelum temanogrel témanogrel temanogrel
3-methoxy-N-{3-(1-methyl-1H-pyrazol-5-yl)-4-[2-(morpholin4-yl)ethoxy]phenyl}benzamide 3-méthoxy-N-{3-(1-méthyl-1H-pyrazol-5-yl)-4-[2-(morpholin4-yl)éthoxy]phényl}benzamide N-{3-(1-metil-1H-pirazol-5-il)-4-[2-(morfolin-4-il)etoxi]fenil}3-metoxibenzamida C24H28N4O4 H3 C H3CO O H N N N O O N
87
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
tiprelestatum tiprelestat tiprélestat tiprelestat
human elafin (elastase-specific inhibitor, skin-derived antileukoproteinase, peptidase inhibitor 3) élafine humaine (inhibiteur spécifique de l'élastase, antileukoprotéinase dérivé de la peau, inhibiteur 3 de peptidase) elafina humana (inhibidor específico de la elastasa, antileukoproteinasa derivada de la piel, inhibidor 3 de peptidasa) C254H416N72O75S10 AQEPVKGPVS MACFVPQ TKPGSCPIIL IRCAMLNPPN RCLKDTDCPG IKKCCEGSCG 50 57
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 16-45 23-49 32-44 38-53
tivantinibum tivantinib tivantinib tivantinib
(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol3-yl)pyrrolidine-2,5-dione (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoléin-1-yl)-4-(1H-indol3-yl)pyrrolidine-2,5-dione (3R,4R)-3-(5,6-dihidro-4H-pirrolo[3,2,1-ij]quinolein-1-il)-4-(1H-indol3-il)pirrolidina-2,5-diona C23H19N3O2 O H N O N
HN
H H
tofogliflozinum tofogliflozin tofogliflozine tofogliflozina
(1S,3'R,4'S,5'S,6'R)-6-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)3',4',5',6'-tetrahydro-3H-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol (1S,3'R,4'S,5'S,6'R)-6-[(4-éthylphényl)méthyl]-6'-(hydroxyméthyl)3',4',5',6'-tétrahydro-3H-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol (1S,3'R,4'S,5'S,6'R)-6-[(4-etilfenil)metil]-6'-(hidroximetil)-3',4',5',6'tetrahidro-3H-espiro[2-benzofurano-1,2'-pirano]-3',4',5'-triol
88
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C22H26O6 CH3
HO O OH HO OH O
trastuzumabum emtansinum # trastuzumab emtansine
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)], humanized monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) Homo sapiens IGHG1*03 (121-449) CH1 R120>K], (223-214')disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; (229-229":232-232")bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker For the emtansine part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"*. immunoglobuline G1-kappa, anti-[Homo sapiens ERBB2 (récepteur 2 du facteur de croissance épidermique, HER-2, p185c-erbB2, NEU, EGFR2)]], anticorps monoclonal humanisé conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) Homo sapiens IGHG1*03 (121-449) CH1 R120>K], (223-214')disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; dimère (229-229":232-232")bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(Nmaléimidométhyl) cyclohexane-1-carboxylate (SMCC) Pour la partie emtasine, veuillez vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*.
trastuzumab emtansine
89
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
trastuzumab emtansina
inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB2 (receptor 2 del factor de crecimiento epidérmico, HER-2, p185c-erbB2, NEU, EGFR2)]], anticuerpo monoclonal humanizado conjugado con maitansinoide DM1; cadena pesada gamma1 (1-449) [VH humanizado (Homo sapiens IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) Homo sapiens IGHG1*03 (121-449) CH1 R120>K], (223-214')disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; dimero (229-229":232-232")bisdisulfuro; conjugado, en 3 a 4 residuos lisil por término medio, con el maitansinoide DM1 mediante un conector succinimidil-4-(Nmaleimidometil) ciclohexano-1-carboxilato (SMCC) Por la parte emtansina, por favor, vaya al documento "INN for pharmaceutical substances: Names for radicals, groups & others"*. Heavy chain / Chaîne lourde / Cadena pesada EVQLVESGGG LVQPGGSLRL SCAASGFNIK IYPTNGYTRY ADSVKGRFTI SADTSKNTAY GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP DYFPEPVTVS WNSGALTSGV HTFPAVLQSS YICNVNHKPS NTKVDKKVEP KSCDKTHTCP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW STYRVVSVLT VLHQDWLNGK EYKCKVSNKA VYTLPPSREE MTKNQVSLTC LVKGFYPSDI LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCRASQDVN ASFLYSGVPS RFSGSRSGTD FTLTISSLQP GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC DTYIHWVRQA LQMNSLRAED LAPSSKSTSG GLYSLSSVVT PCPAPELLGG YVDGVEVHNA LPAPIEKTIS AVEWESNGQP MHEALHNHYT TAVAWYQQKP EDFATYYCQQ SVVCLLNNFY LSKADYEKHK PGKGLEWVAR TAVYYCSRWG GTAALGCLVK VPSSSLGTQT PSVFLFPPKP KTKPREEQYN KAKGQPREPQ ENNYKTTPPV QKSLSLSPG 50 100 150 200 250 300 350 400 449
GKAPKLLIYS 50 HYTTPPTFGQ 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 147-203 264-324 370-428 22''-96'' 147''-203'' 264''-324'' 370''-428'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 223-214' 223''-214''' Inter-H-H 229-229'' 232-232'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 300, 300''
ulimorelinum ulimorelin
(2R,5S,8R,11R)-5-cyclopropyl-11-[(4-fluorophenyl)methyl]2,7,8-trimethyl-2,3,4,5,7,8,10,11,13,14,15,16-dodecahydro6H-1,4,7,10,13-benzoxatetraazacyclooctadecine-6,9,12-trione (2R,5S,8R,11R)-5-cyclopropyl-11-[(4-fluorophényl)méthyl]2,7,8-triméthyl-2,3,4,5,7,8,10,11,13,14,15,16-dodécahydro6H-1,4,7,10,13-benzoxatétraazacyclooctadécine-6,9,12-trione (2R,5S,8R,11R)-5-ciclopropil-11-[(4-fluorofenil)metil]-2,7,8-trimetil2,3,4,5,7,8,10,11,13,14,15,16-dodecahidro-6H-1,4,7,10,13benzoxatetraazaciclooctadecino-6,9,12(5H)-triona
ulimoréline
ulimorelina
90
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C30H39FN4O4
H3C H O
H N H H 3C H N O O N HN H F H CH3 O
umifenovirum umifenovir umifénovir umifenovir
ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate 6-bromo-4-[(diméthylamino)méthyl]-5-hydroxy-1-méthyl2-[(phénylsulfanyl)méthyl]-1H-indole-3-carboxylate d'éthyle 6-bromo-4-[(dimetilamino)metil]-5-hidroxi-1-metil2-[(fenilsulfanil)metil]-1H-indol-3-carboxilato de etilo C22H25BrN2O3S Br HO H3 C N H3 C N CH3 S O O
CH3
umirolimusum umirolimus
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)3-{(1R)-2-[(1S,3R,4R)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]1-methylehyl}-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ªoctadecahydro-23,27-epoxy-5H-pyrido[2,1c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)3-{(1R)-2-[(1S,3R,4R)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]1-methylehyl}-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ªoctadecahydro-23,27-epoxy-5H-pyrido[2,1c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)3-{(1R)-2-[(1S,3R,4R)-4-(2-etoxietoxi)-3-metoxiciclohexil]-1-metiletil}9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-octadecahidro23,27-epoxi-5H-pirido[2,1-c][1,4]oxazaciclohentriacontina1,5,11,28,29(6H,31H)-pentona
umirolimus
umirolimús
91
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
C55H87NO14 O O CH3
H H H3CO
H H N O H H3C O H O O
CH3 H O H3C
H OH O H CH3 CH3 H OCH3 H3C H H CH3
OH H O
H OCH3
uridini triacetas uridine triacetate triacétate d'uridine triacetato de uridina
2',3',5'-tri-O-acetyluridine 2',3',5'-tri-O-acétyluridine 2',3',5'-tri-O-acetiluridina C15H18N2O9 O O O CH3 O O HN N
H3C O
O
O O
CH3
vaniprevirum vaniprevir
(5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[N(cyclopropanesulfonyl)carbamoyl]-2-ethylcyclopropyl}-15,15dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19dodecahydro-1H,3H,5H-2,23:5,8-dimethano-4,13,2,8,11benzodioxatriazacyclohenicosine-7-carboxamide (5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[N(cyclopropanesulfonyl)carbamoyl]-2-éthylcyclopropyl}-15,15diméthyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19dodécahydro-1H,3H,5H-2,23:5,8-diméthano-4,13,2,8,11benzodioxatriazacyclohénicosine-7-carboxamide (5R,7S,10S)-10-terc-butil-N-{(1R,2R)-1-[N(ciclopropanosulfonil)carbamoil]-2-etilciclopropil} -15,15-dimetil3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahidro1H,3H,5H-2,23:5,8-dimetano-4,13,2,8,11benzodioxatriazaciclohenicosina-7-carboxamida
vaniprévir
vaniprevir
92
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C38H55N5O9S
N H3C H3C H3C H3C O H NH O O H CH3 N H O O
O
H N
O
O O S N H CH3
H
vemurafenibum vemurafenib vémurafénib vemurafenib
N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-carbonyl]2,4-difluorophenyl}propane-1-sulfonamide N-{3-[5-(4-chlorophényl)-1H-pyrrolo[2,3-b]pyridin-3-carbonyl]2,4-difluorophényl}propane-1-sulfonamide N-{3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]2,4-difluorofenil}propano-1-sulfonamida C23H18ClF2N3O3S HN N O F F O O S N H
CH3
Cl
verubulinum verubulin vérubuline verubulina
N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine N-(4-méthoxyphényl)-N,2-diméthylquinazolin-4-amine N,2-dimetil-N-(4-metoxifenil)quinazolin-4-amina C17H17N3O CH3 N N N CH3 OCH3
93
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
vidofludimusum vidofludimus vidofludimus vidofludimús
2-[N-(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)carbamoyl]cyclopent1-ene-1-carboxylic acid acide 2-[N-(3-fluoro-3'-méthoxy[1,1'-biphényl]4-yl)carbamoyl]cyclopent-1-ène-1-carboxylique ácido 2-[N-(3-fluoro-3'-metoxi[1,1'-bifenil]-4-il)carbamoil]ciclopent1-eno-1-carboxílico C20H18FNO4 F
H N O
CO2H
OCH3
vilanterolum vilanterol vilantérol vilanterol
4-{(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]1-hydroxyethyl}-2-(hydroxymethyl)phenol 4-{(1R)-2-[(6-{2-[(2,6-dichlorophényl)méthoxy]éthoxy}hexyl)amino]1-hydroxyéthyl}-2-(hydroxyméthyl)phénol 4-{(1R)-2-[(6-{2-[(2,6-diclorofenil)metoxi]etoxi}hexil)amino]1-hidroxietil}-2-(hidroximetil)fenol C24H33Cl2NO5 H OH Cl H N O O Cl OH
HO
vipadenantum vipadenant vipadénant vipadenant
3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine 3-[(4-amino-3-méthylphényl)méthyl]-7-(furan-2-yl)3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine 3-[(4-amino-3-metilfenil)metil]-7-(furan-2-l)-3H-[1,2,3]triazolo[4,5d]pirimidin-5-amina
94
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
C16H15N7O O CH3 N N N N H2N N
NH2
vismodegibum vismodegib vismodégib vismodegib
2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]4-(methanesulfonyl)benzamide 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phényl]4-(méthylsulfonyl)benzamide 2-cloro-N-[4-cloro-3-(piridin-2-il)fenil]-4-(metanosulfonil)benzamida C19H14Cl2N2O3S O O S H3 C
H N Cl O Cl
N
vorapaxarum vorapaxar
ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3fluorophenyl)pyridine-2-yl]ethen-1-yl}-1-methyl3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3-fluorophényl)pyridin2-yl]éthén-1-yl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan6-yl]carbamate d'éthyle [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(1E)-2-[5-(3-fluorofenil)piridin2-il]eten-1-il}-1-metil-3-oxododecahidronafto[2,3-c]furan6-il]carbamato de etilo C29H33FN2O4 O H H H O H H H N H F O O CH3
vorapaxar
vorapaxar
H3C H N
95
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES Recommended International Non Proprietary Names (Rec. INN): List 6 (WHO Chronicle, Vol. 20, No. 11, 1966) dalanatum insulinum dalanated insulin
p. 424
replace the description by the following an insulin derivative prepared by the removal of the C-terminal alanine from the B chain of insulin
Recommended International Non Proprietary Names (Rec. INN): List 31 Denominations communes internationales recommandées (DCI Rec.): Liste 31 Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 31 (WHO Drug Information, Vol. 5, No. 3, 1991) p. 13 delete/supprimer/suprimáse suplatastum tosilas insert/insérer/insertese suplatasti tosilas
Recommended International Non Proprietary Names (Rec. INN): List 51 Denominations communes internationales recommandées (DCI Rec.): Liste 51 Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 51 (WHO Drug Information, Vol. 18, No. 1, 2004) p. 102 delete/supprimer/suprimáse ralfinamidum ralfinamide ralfinamide ralfinamida insert/insérer/insertese priralfinamidum priralfinamide priralfinamide priralfinamida
Recommended International Non Proprietary Names (Rec. INN): List 59 Denominations communes internationales recommandées (DCI Rec.): Liste 59 Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 59 (WHO Drug Information, Vol. 22, No. 1, 2008) p. 66 delete/supprimer/suprimáse sergliflozinum etabonas insert/insérer/insertese sergliflozini etabonas
Recommended International Non Proprietary Names (Rec. INN): List 63 Denominations communes internationales recommandées (DCI Rec.): Liste 63 Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 63 (WHO Drug Information, Vol. 24, No. 1, 2010) p. 56 fonturacetamum fonturacetam fonturacétam fonturacetam
replace the chemical name by the following remplacer le nom chimique par le suivant sustitúyase el nombre químico por el siguiente rac-2-(2-oxo-4-phenylpyrolidin-1-yl)acetamide rac-2-(2-oxo-4-phénylpyrolidin-1-yl)acétamide rac-2-(4-fenil-2-oxopirolidin-1-il)acetamida
96
WHO Drug Information, Vol. 25, No. 1, 2011
Recommended INN: List 65
p. 74
sifalimumabum sifalimumab sifalimumab sifalimumab
replace the description by the following remplacer la description par la suivante sustitúyase la descripción por la siguiente immunoglobulin G1-kappa, anti-[Homo sapiens interferon alpha (IFN-alpha)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV1-18*01 (95.90%) (IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)], (219-213')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01 (99.00%) –IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (225-225'':228-228'')-bisdisulfide dimer immunoglobuline G1-kappa, anti-[Homo sapiens interféron alpha (IFN-alpha)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV1-18*01 (95.90%) (IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)], (219-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo sapiens VKAPPA (IGKV3-20*01 (99.00%) –IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'215')]; dimère (225-225'':228-228'')-bisdisulfure inmunoglobulina G1-kappa, anti-[interferón alfa (IFN-alfa) de Homo sapiens], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV1-18*01 (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)], (219-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*01 (99.00%) – IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (225225'':228-228'')-bisdisulfuro
Recommended International Non Proprietary Names (Rec. INN): List 64 Denominations communes internationales recommandées (DCI Rec.): Liste 64 Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 64 (WHO Drug Information, Vol. 24, No. 3, 2010) p. 260 afatinibum afatinib afatinib afatinib
replace the chemical name by the following remplacer le nom chimique par le suivant sustitúyase el nombre químico por el siguiente (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-{[(3S)-oxolan3-yl]oxy}quinazolin-6-yl]-4-(dimethylamino)but-2-enamide (2E)-N-[4-(3-chloro-4-fluoroanilino]-7-{[(3S)-oxolan3-yl]oxy}quinazolin-6-y]-4-(diméthylamino)but-2-énamide (2E)-N-[4-(3-cloro-4-fluoroanilino)-7-{[(3S)-oxolan3-il]oxi}quinazolin-6-il]-4-(dimetilamino)but-2-enamida
97
Recommended INN: List 65
WHO Drug Information, Vol. 25, No. 1, 2011
p. 279
sotaterceptum sotatercept sotatercept sotatercept
replace the description by the following remplacer la descriptions par la suivante sustitúyase la descripción por la siguiente fusion protein for immune applications (FPIA) comprising Homo sapiens ACVR2A (activin receptor type 2A, activin receptor type IIA) fragment fused with Homo sapiens immunoglobulin G1 Fc fragment; Homo sapiens ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl linker (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [Homo sapiens IGHG1*03 hinge (120-127), CH2, A115>V (227) (128-237), CH3 (238344)]; (123-123':126-126')-bisdisulfide dimer protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d’Homo sapiens ACVR2A (récepteur type 2A de l’activine, récepteur type IIA de l’activine) fusionné au fragment Fc de l’Homo sapiens immunoglobuline G1; fragment précurseur 21-135 de Homo sapiens ACVR2A (1-115) -linker thréonyl-triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120344) [Homo sapiens IGHG1*03 charnière (120-127), CH2, A115>V (227) (128237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVR2A (receptor tipo 2A de la activina, receptor tipo IIA de la activina) de Homo sapiens fusionado al fragmento Fc de la inmunoglobulina G1 de Homo sapiens; fragmento precursor 21-135 de ACVR2A de Homo sapiens (1-115)-conector treonil-triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-344) [Homo sapiens IGHG1*03 bisagra(120-127), CH2, A115>V (128-237), CH3 (238-344)]; dímero (123-123':126-126')-bisdisulfuro
# Electronic structure available on Mednet: http://mednet.who.int/ # Structure electronique disponible sur Mednet: http://mednet.who.int/ # Estructura electrónica disponible en Mednet: http://mednet.who.int/
* "INN for pharmaceutical substances: Names for radicals, groups & others" document available at / document disponible à / documento disponible en : http://www.who.int/medicines/services/inn/publication/en/index.html
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists only. Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.
98